Immune Dysregulation Translational Research Program

The Immune Dysregulation (IDR) Translational Research Program at Sidra Medicine focuses on understanding, diagnosing, and treating disorders arising from dysfunction of the immune system. These conditions include a broad spectrum of diseases ranging from rare monogenic inborn errors of immunity to more common autoimmune, allergic, and inflammatory disorders.

Immune dysregulation presents a significant clinical challenge due to its heterogeneity, overlap of symptoms across organ systems, and often limited availability of definitive diagnostic and therapeutic strategies.

The IDR Program seeks to address these challenges by integrating clinical care, genomics, immunology, and functional biology within a unified translational framework, enabling improved diagnosis and mechanism-driven interventions.

Mission and Vision

Mission
The mission of the IDR Program is to advance the understanding and management of immune dysregulation disorders through patient-centered translational research that integrates clinical expertise, multi-omics technologies, and functional immunology.

Vision
The program aims to position Sidra Medicine as a regional and international leader in immune dysregulation research by translating biological insights into precision diagnostics and targeted therapeutic strategies, ultimately improving outcomes for patients affected by immune-mediated diseases.

Strategic Pillars and Themes

The IDR Program is structured around four integrated strategic pillars aligned with Sidra Medicine’s precision medicine mission:

Screening and Early Detection
Development of clinically guided screening approaches to identify immune dysregulation at earlier stages, particularly in patients with atypical, severe, or treatment-resistant disease presentations. This includes integration of clinical phenotyping with genomic and immunological profiling.

Biorepositories and National Resources
Establishment of high-quality biobanks and annotated clinical registries for patients with immune dysregulation disorders. These resources support longitudinal studies, facilitate regional collaboration, and enable scalable translational research.

Advanced Diagnostics
Implementation and optimization of cutting-edge diagnostic technologies, including genomic sequencing, immune profiling, and biomarker discovery, to improve diagnostic yield and enable more precise disease classification.

Personalized and Mechanism-Driven Therapies
Translation of molecular and cellular insights into targeted therapeutic strategies, including immune-modulating therapies and individualized treatment approaches guided by patient-specific disease mechanisms.

Gold Cohorts

The IDR Program is anchored by priority Gold Cohorts selected based on clinical need, translational potential, and relevance to the population in Qatar and the MENA region:

Monogenic Disorders of Immune Dysregulation
Rare inborn errors of immunity characterized by autoimmunity, autoinflammation, or immune deficiency.
Inflammatory Bowel and Immune-Mediated Gastrointestinal Disorders
Including early-onset and treatment-resistant forms with underlying immune dysregulation.

These priority cohorts enable systematic patient recruitment, standardized data and biospecimen collection, and integration of clinical and molecular datasets to drive discovery and translation.

Program Scope and Approach

The IDR Program adopts a comprehensive translational approach that:

Bridges clinical observation and laboratory discovery
Integrates multi-omics, immunophenotyping, and functional validation
Leverages multidisciplinary expertise across immunology, genomics, gastroenterology, rheumatology, and related fields
Supports both rare disease discovery and insights into more common immune-mediated disorders

Although many immune dysregulation conditions are rare, studying these disorders provides valuable insights into fundamental immune pathways, which may inform therapeutic strategies across a broader spectrum of diseases.

Collaborative and Translational Impact

The IDR Program functions as a cross-cutting program within Sidra Medicine’s translational research ecosystem, bringing together clinicians, scientists, and collaborators to accelerate the translation of research findings into clinical applications.

By embedding research within clinical care pathways, the program aims to: